Qualitative structure residue relationship analysis in the determination of the maximum residue limit of veterinary drugs

Chemosphere

Volumn 87, Issue 4, 2012, Pages 312-318

  Grabowski, Tomasz ^a   Jaroszewski, Jerzy Jan ^b   Piotrowski, Walerian ^c   Feder, Marcin ^d  

^a Centre of Pharmacokinetics Research FILAB   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^c INSTITUTE OF CARDIOLOGY   (Poland)

^d Pieńków 149 ^*  (Poland)

Author keywords

In silico; MRL; Muscle tissue; QSRR; Residues; Solubility

Indexed keywords

SOLUBILITY; STATISTICAL METHODS;

FOOD-PRODUCING ANIMALS; IN-SILICO; LEAVE-ONE-OUT CROSS VALIDATIONS; MAXIMUM RESIDUE LIMITS; MUSCLE TISSUES; PHYSICOCHEMICAL PARAMETERS; QSRR; RESIDUES;

MUSCLE;

ABAMECTIN; CARAZOLOL; CIPERMETHRIN; CLENBUTEROL; CLORSULON; CYFLUTHRIN; DELTAMETHRIN; DEXAMETHASONE; DICLOFENAC; DIMPYLATE; DORAMECTIN; EPRINOMECTIN; FENVALERATE; FIROCOXIB; FLUGESTONE ACETATE; FLUMETHRIN; FLUNIXIN; HALOFUGINONE; IVERMECTIN; LASALOCID; LEVAMISOLE; MELOXICAM; METHYLPREDNISOLONE; MONENSIN; OXYCLOZANIDE; PHOXIM; PREDNISOLONE; RAFOXANIDE; UNINDEXED DRUG; VETERINARY DRUG;

CORRELATION; DRUG; GENE EXPRESSION; MATHEMATICAL ANALYSIS; MUSCLE; PHYSICOCHEMICAL PROPERTY; QUALITATIVE ANALYSIS; SOLUBILIZATION;

ARITHMETIC; ARTICLE; CHEMICAL STRUCTURE; COMPUTER MODEL; DRUG CONCENTRATION; FOOD INDUSTRY; IC 50; MAXIMUM RESIDUE LIMIT; MUSCLE TISSUE; NONHUMAN; PHYSICAL CHEMISTRY; VALIDATION PROCESS;

ANIMALIA;

EID: 84857500288     PISSN: 00456535     EISSN: 18791298     Source Type: Journal    
DOI: 10.1016/j.chemosphere.2011.12.003     Document Type: Article

References (34)

1. ACD/ChemSketch v. 12.0, 2010. Advanced Chemistry Development. http://www.acdlabs.com/resources/freeware/chemsketch/.
2. Bonora E., Willeit J., Kiechl S., Oberhollenzer F., Egger G., Bonadonna R., Muggeo M. Relationship between insulin and carotid atherosclerosis in the general population. Bruneck Study Stroke 1997, 6:1147-1152.
3. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci 1999, 88:807-814.
4. Concordet D., Toutain P.L. The withdrawal time estimation of veterinary drugs: a non-parametric approach. J. Vet. Pharmacol. Ther. 1997, 20:374-379.
5. European Commission, 2005. Notice to applicants and guideline veterinary medicinal products establishment of maximum residue limits (MRLs) for residues of veterinary medicinal products in foodstuffs of animal origin. pp. 1-79.
6. European Commission, 2008. Draft opinion on use of the threshold of toxicological concern (TTC) approach for the safety assessment of chemical substances. pp. 1-47.
7. European Commission, 2009. Regulation (EC) No. 470/2009. pp. 1-12.
8. European Medicines Agency, 2006. On the limits of genotoxic impurities. EMEA/CHMP/QWP/251344/2006. pp. 1-8.
9. EPI Suite™ v. 4.0, 2010. United States Environmental Protection Agency. http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm.
10. Goldenberg N., Glueck C.J., Loftspring M., Sherman A., Wang P. Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism 2005, 54:113-121.
11. Grabowski T., Jaroszewski J.J. Bioavailability of veterinary drugs in vivo and in silico. J. Vet. Pharmacol. Ther. 2009, 32:249-257.
12. Grabowski T., Jaroszewski J.J., Piotrowski W. Correlations between no observed effect level and selected parameters of the chemical structure for veterinary drugs. Toxicol. In Vitro. 2010, 24:953-959.
13. Haritova A.M., Fink-Gremmels J. A simulation model for the prediction of tissue:plasma partition coefficients for drug residues in natural casings. Vet. J. 2009, 185:278-284.
14. Hou T., Li Y., Zhang W., Wang J. Recent developments of in silico predictions of intestinal absorption and oral bioavailability. Comb. Chem. High Throughput. Screen. 2009, 12:497-506.
15. Ioakimidis L., Thoukydidis L., Mirza A., Naeem S., Reynisson J. Benchmarking the reliability of QikProp. correlation between experimental and predicted values. QSAR Comb. Sci. 2007, 27:445-456.
16. Kubinyi, H., 1993. QSAR: Hansch analysis and related approaches. Methods and principles. vol. 1. Wiley-VCH. pp. 20-190.
17. Leon A.C., Hedeker D. Quintile stratification based on a misspecified propensity score in longitudinal treatment effectiveness analyses of ordinal doses. Comput. Stat. Data Anal. 2007, 51:6114-6122.
18. Lin L., Lin W.Q., Jiang J.H., Shen G.L., Yu R.Q. QSAR analysis of substituted bis[(acridine-4-carboxamide)propyl]methylamines using optimized block-wise variable combination by particle swarm optimization for partial least squares modeling. Eur. J. Pharm. Sci. 2005, 25:245-254.
19. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
20. Lipinski C.A. Single-mode compound retrieval for QSAR, QSPR data sets, and batch mode exact structure searching. J. Pharm. Sci. 2002, 91:2470-2472.
21. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
22. Mattisson I., Wirfält E., Andrén C., Gullberg B., Berglund G. Dietary fat intake-food sources and dietary correlates in the Malmö Diet and Cancer cohort. Public Health Nutr. 2003, 6:559-569.
23. Melagraki G., Afantitis A., Sarimveis H., Igglessi-Markopoulou O., Koutentis P.A., Kollias G. In silico exploration for identifying structure-activity relationship of MEK inhibition and oral bioavailability for isothiazole derivatives. Chem. Biol. Drug Des. 2010, 76:397-406.
24. Organisation for Economic Co-operation and Development, 2004. The report from the expert group on (Quantitative) Structure-Activity Relationships [(Q)SARs] on the principles for the validation of (Q)SARs. pp. 11-198.
25. Organisation for Economic Co-operation and Development, 2007. Guidance document on the validation of (quantitative) structure-activity relationships [(Q)SAR] models, OECD, series on testing and assessment No. 69. pp. 1-154.
26. Pratim R.P., Paul S., Mitra I., Roy K. On two novel parameters for validation of predictive QSAR models. Molecules 2009, 14:1660-1701.
27. QuicProp 3.1 from Schrödinger v 31207, 2007. Schrödinger, LLC. http://www.schrodinger.com/products/14/17/.
28. Rom W.N., Markowitz S.B. Environmental and Occupational Medicine. fifth ed. 2007, Lippincott Williams and Wilkins, pp. 60.
29. SAS v 9.2, 2010. SAS Institute Inc. http://www.sas.com/software/sas9/.
30. Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol. In Vitro. 2008, 22:457-467.
31. Witte I., Jacobi H., Juhl-Strauss U. Correlation of synergistic cytotoxic effects of environmental chemicals in human fibroblasts with their lipophilicity. Chemosphere 1995, 31:4041-4049.
32. Woodward N.K. The use of microbiological end-points in the safety evaluation and elaboration of maximum residue limits for veterinary drugs intended for use in food producing animals. J. Vet. Pharmacol. Ther. 1998, 21:47-53.
33. World Health Organization, 2007. Guidance document on the validation of (quantitative) structure-activity relationships [(Q)SAR] models. WHO, ENV/JM/MONO(2007)2 2007. pp. 2-135.
34. Yokogawa K., Ishizaki J., Ohkuma S., Miyamoto K. Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model. Methods Find Exp. Clin. Pharmacol. 2002, 24:81-93.